Inhibition of NRP-2 function through the application of specific monoclonal antibodies has been shown to result in a significant reduction in tumor-associated lymphangiogenesis, as well as a decrease in metastasis to lymph nodes and other distant sites [30]. This evidence concerns the gene NRP2 and neoplasm.